These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

814 related items for PubMed ID: 27068398

  • 1. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
    Dziadziuszko R, Le AT, Wrona A, Jassem J, Camidge DR, Varella-Garcia M, Aisner DL, Doebele RC.
    J Thorac Oncol; 2016 Aug; 11(8):1273-1281. PubMed ID: 27068398
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, André F, Soria JC, Friboulet L.
    Clin Cancer Res; 2016 Dec 15; 22(24):5983-5991. PubMed ID: 27401242
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
    Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ.
    N Engl J Med; 2014 Nov 20; 371(21):1963-71. PubMed ID: 25264305
    [Abstract] [Full Text] [Related]

  • 6. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
    Zhang L, Jiang T, Li X, Wang Y, Zhao C, Zhao S, Xi L, Zhang S, Liu X, Jia Y, Yang H, Shi J, Su C, Ren S, Zhou C.
    Cancer; 2017 Aug 01; 123(15):2927-2935. PubMed ID: 28346673
    [Abstract] [Full Text] [Related]

  • 7. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
    Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC.
    PLoS One; 2013 Aug 01; 8(12):e82236. PubMed ID: 24349229
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
    Pailler E, Auger N, Lindsay CR, Vielh P, Islas-Morris-Hernandez A, Borget I, Ngo-Camus M, Planchard D, Soria JC, Besse B, Farace F.
    Ann Oncol; 2015 Jul 01; 26(7):1408-15. PubMed ID: 25846554
    [Abstract] [Full Text] [Related]

  • 10. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
    Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, Engelman JA, Fujita N.
    Clin Cancer Res; 2015 Jan 01; 21(1):166-74. PubMed ID: 25351743
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH, Grauslund M, Urbanska EM, Melchior LC, Rask CK, Costa JC, Skov BG, Sørensen JB, Santoni-Rugiu E.
    BMC Res Notes; 2013 Nov 26; 6():489. PubMed ID: 24279718
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review.
    Xu CW, Wang WX, Huang RF, He C, Liao XH, Zhu YC, Du KQ, Zhuang W, Chen YP, Chen G, Fang MY.
    Thorac Cancer; 2017 Nov 26; 8(6):714-719. PubMed ID: 28845578
    [Abstract] [Full Text] [Related]

  • 16. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
    Morris TA, Khoo C, Solomon BJ.
    Drugs; 2019 Aug 26; 79(12):1277-1286. PubMed ID: 31313100
    [Abstract] [Full Text] [Related]

  • 17. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A, Casaluce F, Maione P, Gridelli C.
    Expert Rev Anticancer Ther; 2018 Jan 26; 18(1):71-80. PubMed ID: 29187012
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
    Xu S, Wang W, Xu C, Li X, Ye J, Zhu Y, Ge T.
    BMC Cancer; 2019 Aug 05; 19(1):769. PubMed ID: 31382924
    [Abstract] [Full Text] [Related]

  • 20. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
    Loong HH, Mok K, Leung LK, Mok TS.
    Future Oncol; 2015 Aug 05; 11(5):735-45. PubMed ID: 25757678
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.